Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.66 |
| ▸ | LMNA | P02545 | 6/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 5/20 | 0.63 |
| ▸ | STAT3 | P40763 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1024585 | 0.90 | SMN1; SMN2 (0.73) | SMN1; SMN2LMNAALOX15TSHRTDP1 | |
| SCHEMBL22307532 | 0.87 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAALOX15TSHRTDP1 | |
| SCHEMBL501944 | 0.84 | SMN1; SMN2 (0.85) | SMN1; SMN2LMNAALOX15TSHRTDP1 | |
| SCHEMBL14423493 | 0.84 | SMN1; SMN2 (0.85) | SMN1; SMN2LMNAALOX15TSHRTDP1 | |
| SCHEMBL92599 | 0.84 | SMN1; SMN2 (0.85) | SMN1; SMN2LMNAALOX15TSHRTDP1 | |
| SCHEMBL5374402 | 0.84 | SMN1; SMN2 (0.85) | SMN1; SMN2LMNAALOX15TSHRTDP1 | |
| SCHEMBL3161153 | 0.84 | TDP1 (0.84) | SMN1; SMN2LMNAALOX15TSHRTDP1 | |
| SCHEMBL30294105 | 0.84 | TDP1 (0.84) | SMN1; SMN2LMNAALOX15TSHRTDP1 | |
| SCHEMBL9814242 | 0.84 | TDP1 (0.84) | SMN1; SMN2LMNAALOX15TSHRTDP1 | |
| SCHEMBL2331250 | 0.83 | TDP1 (0.81) | SMN1; SMN2LMNAALOX15TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115974788-B | Method for synthesizing alpha-straight-chain alkyl substituted heteroarene | 苏州大学 | 2025-06-17 | — | — | CN | disclosed |
| CN-115974788-A | Method for synthesizing alpha-linear alkyl substituted heteroarene | 苏州大学 | 2023-04-18 | — | — | CN | disclosed |
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | YODA THERAPEUTICS INC. (TW) | 2023-01-19 | — | — | US | disclosed |
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230018423-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF DISEASES AND DISORDERS MEDIATED BY NLRP3 | NLRP3, NOD1, NLRP1 | SMN1; SMN2 1282/4885LMNA 574/4885ALOX15 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.